

US 20230303634A1

(19) **United States**

(12) **Patent Application Publication**

Xia et al.

(10) **Pub. No.: US 2023/0303634 A1**

(43) **Pub. Date: Sep. 28, 2023**

(54) **OMICRON SARS-COV-2 ASSAY**

(71) Applicant: **Board of Regents, The University of Texas System**, Austin, TX (US)

(72) Inventors: **Hongjie Xia**, Galveston, TX (US); **Xuping Xie**, Galveston, TX (US); **Pei-Yong Shi**, Galveston, TX (US)

(21) Appl. No.: **18/076,315**

(22) Filed: **Dec. 6, 2022**

Related U.S. Application Data

(60) Provisional application No. 63/307,195, filed on Feb. 7, 2022.


Publication Classification

(51) **Int. Cl.**
C07K 14/165 (2006.01)
G01N 33/569 (2006.01)

(52) **U.S. Cl.**
CPC *C07K 14/165* (2013.01); *G01N 33/56983* (2013.01); *C07K 2319/60* (2013.01)

(57) **ABSTRACT**
Certain embodiments of the invention include recombinant reverse genetic systems for Omicron variant of SARS-CoV-2 virus.

Specification includes a Sequence Listing.






FIG. 1A-1B




FIG. 5A-5B




FIG. 6A-6B

